AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00664352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannose-6-Phosphate (Juvidex)
Description: * 100µL of 300mM (8.46 mg/100μL) Juvidex will be injected intradermally into each cm2 of one 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of 300mM (8.46 mg/100μL) Juvidex will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest.~* 100µL of placebo will be injected intradermally into each cm2 of the other 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of placebo will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest.
Study NCT00664352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannose-6-Phosphate (Juvidex)
Description: * 100µL of 600mM(16.93 mg/100μL) Juvidex will be injected intradermally into each cm2 of one 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of 600mM (16.93 mg/100μL) Juvidex will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest.~* 100µL of placebo will be injected intradermally into each cm2 of the other 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of placebo will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest.
Study NCT00664352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannose-6-Phosphate (Juvidex)
Description: * 300µL of 300mM (8.46 mg/100μL) Juvidex will be applied topically to one 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest.~* 300µL of placebo will be applied topically to the other 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest.
Study NCT00664352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannose-6-Phophate (Juvidex)
Description: * 300µL of 600mM (16.93 mg/100μL) Juvidex will be applied topically to one 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest.~* 300µL of placebo will be applied topically to the other 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest.
Study NCT00664352 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: * 100µL of placebo will be injected intradermally into each cm2 of one 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of placebo will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest.~* Standard Care (moist wound healing dressings alone) will be applied to the other 3cm2 donor site.
Study NCT02315144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV48108
Description: TV48108 15, 60, 120 μg
Study NCT02315144 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study NCT01575418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rectal formulation (RF) of tenofovir 1% gel
Description: The RF is translucent colorless viscous gel formulation containing 1% (w/w) of tenofovir (PMPA) formulated in purified water with EDTA, glycerin, methylparaben, propylparaben, carbopol, sodium carboxy methyl cellulose, and pH adjusted to 7. The RF is close to isoosmolar with an osmolality of 479 mOsmol/kg.
Study NCT01575418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal formulation (VF) of tenofovir 1% gel
Description: The original VF is a transparent, viscous gel formulation containing 1% (weight/ weight or w/w) of tenofovir (PMPA, 9-\[(R)-2-(phosphonomethoxy)propyl\]adenine monohydrate), formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben, hydroxyethylcellulose, and pH adjusted to 4-5. This formulation has been used in all clinical trials (vaginal, penile, and rectal) of tenofovir 1% gel to date.
Study NCT01575418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reduced glycerin vaginal formulation (RGVF) of tenofovir 1% gel
Description: Modified slightly from the original VF formulation, the RGVF has a lower glycerin content than the VF and a significantly reduced osmolality (836 or 846 versus 3111 mOsmol/kg). Lowering glycerin content lowered the viscosity, so the HEC concentration was increased by 10% (a change considered to be insignificant). The amount of parabens was increased by 10% each to improve the antimicrobical effectiveness. The RGVF formulation with 2.75% HEC was used in MTN-007 (CONRAD IND 73,382; currently enrolling), which is the only clinical study of this formulation. The RGVF formulation has since been modified to increase the viscosity.
Study NCT01575418 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiolabeling of study drugs and semen
Description: Study products (i.e. the gel formulations) will be radiolabeled with 111In-DTPA, an FDA-approved radiopharmaceutical commonly used in diagnostic nuclear medicine studies. The delivered dose per gel study product will be approximately 100 microCuries (µCi) to allow sufficient visualization for the imaging period.~Autologous whole semen collected from the participants at designated visits will be radiolabeled with a delivered dose of approximately 500 microCuries (µCi) of 99mTc-sulfur colloid, also an FDA-approved radiopharmaceutical commonly used in diagnostic nuclear studies. The study team at JHU has extensive experience administering these radiopharmaceuticals rectally. Both of these radiopharmaceuticals will be prepared and delivered by a commercial radiopharmacy and mixed by the study investigators with the respective gel and whole semen vehicles.~The study product and autologous whole semen will be loaded into calibrated syringes with luer lock adapter for dosing.
Study NCT01852461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Poractant alfa
Description: porcine lung extract, initial dosing is 200 mg/kg (2.5 mL/kg) and repeated dosing is given at 100 mg/kg (1.25 mL/kg) every 12 hours, up to maximum of two additional doses when indicated
Study NCT03137043 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Subjects will be given an Electronic Case Report Form (eCRF) with a series of questionnaire such as Asthma Control Test, Morisky-Green Questionnaire and St George's Respiratory Questionnaire.
Study NCT03137043 — intervention group
Intervention type: OTHER
Intervention: Software of Big Data
Description: Software of big data is a powerful data treatment algorithm works closely with Spanish Data Protection Agency as an example on how to reuse clinical information without conflicting with necessary data privacy. The system will process a vast amount of information (big data), so that the impact of random errors will be minimized.
Study NCT02132832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Description: Buspirone is an anxiolytic compound marked by modulation of both 5-HT1A and D3 receptors. Buspirone is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks. 10 mg buspirone is administered on days 1-4, then the dose is increased by 10 mg every 3 days to a maximum of 40 mg buspirone on days 10-19.
Study NCT02132832 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks.
Study NCT05338125 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micro-electrode measurement
Description: Electrophysiological measurement with single-unit micro-electrode
Study NCT03461770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Patients will receive general anesthesia induction with CPAP at 5 cmH20 via face mask with a circular system. CPAP will use before extubation.The air-test will perform during anesthesia with transitory decreases inspired fraction of oxygen to 0.21 over a 5 min period. Recruitment maneuver will be perform if the air test is positive, ( SpO2 is ≤ 96%)
Study NCT01849640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DHA-piperaquine and Primaquine
Description: Subject will be enrolled in open label fashion to a 3-day treatment course of DHA-piperaquine (DP) by directly observed therapy (DOT, all patients will receive a total of 9 tablets containing 40mg DHA and 320mg of piperaquine in divided doses at 0, 24 and 48 hours (3 tablets once per day) for the 3 day course. At completion of DP treatment volunteers will be randomized in an open label fashion to receive a single 45 mg dose of primaquine or no therapy.
Study NCT04148989 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Code Sepsis protocol (full implementation)
Description: Implementation of a coordinated, structured, multidisciplinary team-based protocol for initial evaluation and treatment of ED patients with suspected sepsis.
Study NCT02251769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir
Study NCT02251769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Study NCT02251769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Study NCT02251769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-Fat Test Meal
Study NCT03015129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Study NCT03015129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Study NCT01102764 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Prolonged Exposure (PE) therapy provided at patients house via telemedicine
Study NCT01102764 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In Person
Description: PE therapy delivered in person at the VAMC
Study NCT04615195 — intervention group
Intervention type: OTHER
Intervention: cries 13 questionnaire
Description: Participant will be contacted by telephone by a clinical research assistant to answer the CRIES 13 questionnaire.~In large families, the CRIES-13 of the holder of parental authority and of the child will be applied for each of them whose age corresponds to the inclusion criteria.
Study NCT03033940 — intervention group
Intervention type: RADIATION
Intervention: Observational use of fluoroscopy
Study NCT03151070 — intervention group
Intervention type: OTHER
Intervention: QVLM Intervention package
Description: QVLM intervention package consists of 3 simultaneous interventions:~* Social marketing to promote insitutional deliveries.~* PRONTO training to public health personnel~* Improve interaction with traditional birth attendants
Study NCT03214653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Subjects were given target-controlled infusion of propofol using Schinder technique effect mode with the administration of maintenance agent was adjusted by the depth of sedation using bispectral index monitor with target of 45-50
Study NCT03214653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Subjects were given sevoflurane 1,5-2% as maintenance agent of anesthesia.
Study NCT00963612 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: BOLD MRI test
Description: Additional MR pulse sequence performed on BOLD MRI is expected to increase the regular scan time by an additional 5-10 minutes. No intravenous contrast is required for BOLD acquisition.
Study NCT02145338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin or Trimethoprim or Cefalexin
Description: Antibiotic prophylaxis
Study NCT02145338 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No prophylaxis
Description: Discrete treatment courses of antibiotics as indicated by symptoms or signs of UTI.
Study NCT00250549 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Post test video
Description: We compared the educational effectiveness of a 15-minute posttest counseling video with the normal practice of a session with an HIV counselor.Patients in the experimental group watched an HIV posttest educational video.
Study NCT02194504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary advice, Western
Description: Dietary advice, guided by professional dieticians. Caloric restricted (-30en%) diet with Western type nutrient composition (SFA, carbohydrates, sugars, fruit juice, meat, dairy)
Study NCT02194504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary advice, Targeted
Description: Dietary advice, guided by professional dieticians. Caloric restricted (-30en%) diet with nutrient composition aiming at an improvement in organ health and a reduction in liver fat (PUFA, fish, soy protein, whole grain)
Study NCT00968825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A
Description: RT001 (Botulinum Toxin Type A Topical Gel) Dose D applied topically at Baseline (Day 0) to the lateral canthal lines
Study NCT00968825 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (Dose E) applied topically at Baseline (Day 0) to the lateral canthal lines
Study NCT03390959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Training
Description: Individuals in the Trained Group will perform the training twice a week for 45 minutes and perform for a period of 12 weeks.~The training is divided into a pre-training phase where general hip dissociation exercises and simple stretching of the hip flexor and extensor muscle groups, knee, foot and paravertebral are performed.~The second phase is the proprioceptive training, where it will involve training of balance, sensitivity and proprioception, being used a circuit composed of 15 stations, whose time of stay in each station is 2 minutes.~And finally the third stage are relaxation exercises, performed with breathing exercises associated with slow active movements of the joints.
Study NCT03390959 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Will not be submitted to any physical intervention. It continues in your daily life with only phone monitoring.
Study NCT00376077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone and IVIG
Description: Combination therapy (IV MP (Solu-Medrol®, Upjohn) 30 mg/kg (max. 1 g) over 1 hour followed by IVIG 1 g/kg (Gamunex Immune Globulin Intravenous \[Human\], 10%; Bayer)\* x 1 dose
Study NCT00376077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo and IVIG
Description: Placebo followed by IVIG 1 g/kg (Gamunex Immune Globulin Intravenous \[Human\], 10%; Bayer)\* x 1 dose
Study NCT00835653 — intervention group
Intervention type: PROCEDURE
Intervention: median nerve block
Description: median nerve block performed under echographic guidance
Study NCT01408420 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MAP > 60 mmHg
Description: During heart surgery a blood pressure with a MAP > 60 mmHg during extracorporeal circulation is used.
Study NCT03129126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-10
Description: Intravesical tacrolimus
Study NCT02922023 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambulatory blood pressure monitor (ABPM)
Description: ABPM allows providers to obtain blood pressure readings over a 24 hour period, to assess blood pressure at night to determine dipping status, and to evaluate the efficacy of anti-hypertensive therapy.
Study NCT02922023 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chronotherapy
Description: Chronotherapy group will receive a shift in the timing of one of their antihypertensive medications to nighttime dosing without consulting their ABPM results.
Study NCT03560752 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
Description: Given via injection
Study NCT00233974 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET (positron emission tomography)
Description: Following conventional segmental mastectomy with or without needle localization, the patient will then undergo intraoperative PET-probe evaluation
Study NCT03808701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT200
Description: Recombinant Anti-EGFR Monoclonal Antibody
Study NCT03535831 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL
Description: The purpose of this study is to determine if use of 18F-DCFPyL would increase the detection of lesions and to better inform your oncologist on the best method of treatment for your disease.
Study NCT02594657 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pedal rate on 50 RPM
Description: All measurements are performed in two pedalling situations. The two frequencies used will be 50 and 80 RPM. For each subject the running order (50 and 80, 80 and 50) is randomly determined
Study NCT01575418 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiolabeling of study drugs and semen
Description: Study products (i.e. the gel formulations) will be radiolabeled with 111In-DTPA, an FDA-approved radiopharmaceutical commonly used in diagnostic nuclear medicine studies. The delivered dose per gel study product will be approximately 100 microCuries (µCi) to allow sufficient visualization for the imaging period.~Autologous whole semen collected from the participants at designated visits will be radiolabeled with a delivered dose of approximately 500 microCuries (µCi) of 99mTc-sulfur colloid, also an FDA-approved radiopharmaceutical commonly used in diagnostic nuclear studies. The study team at JHU has extensive experience administering these radiopharmaceuticals rectally. Both of these radiopharmaceuticals will be prepared and delivered by a commercial radiopharmacy and mixed by the study investigators with the respective gel and whole semen vehicles.~The study product and autologous whole semen will be loaded into calibrated syringes with luer lock adapter for dosing.
Study NCT02594657 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pedal rate on 80 RPM
Description: All measurements are performed in two pedalling situations. The two frequencies used will be 50 and 80 RPM. For each subject the running order (50 and 80, 80 and 50) is randomly determined
Study NCT00770887 — intervention group
Intervention type: PROCEDURE
Intervention: Self administration
Description: Subjects will self administer injections of 104 mg of the subcutaneous formulation of depot medroxyprogesterone acetate (depo-subQ provera 104).
Study NCT00443924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INS115644 Ophthalmic Solution
Description: One drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for three days
Study NCT00443924 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One drop of placebo in each eye every 12 hours for three days
Study NCT00443924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INS115644 Ophthalmic Solution
Description: One drop of Concentration #2 in one eye and one drop of placebo in the contralateral eye every twelve hours for three days
Study NCT00443924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INS115644 Ophthalmic Solution
Description: One drop of Concentration #3 in one eye and one drop of placebo in the contralateral eye every twelve hours for three days
Study NCT00443924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INS115644 Ophthalmic Solution
Description: One drop of Concentration #4 in one eye and one drop of placebo in the contralateral eye every twelve hours for three days
Study NCT02234505 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prosthetic alignment perturbation
Description: Prosthetic ankle plantar-flexion will be modified in different degrees, devices (prosthetic components) will not be modified from baseline condition
Study NCT03832270 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parents InC
Description: Based on social learning theory, Parents InC has been designed specifically for parents of children with an ADHD diagnosis with a particular focus on parenting sense of self competence.
Study NCT03832270 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Incredible Years
Description: Also based on social learning theory but focus is not specifically on ADHD.
Study NCT02574845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Study NCT02574845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin HCl
Study NCT02574845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Study NCT00657735 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: H-Coil deep TMS
Description: 20 daily deep rTMS treatments
Study NCT00657735 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham
Description: inactive treatment
Study NCT01399697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: orally, Week 1 - 16
Study NCT01399697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: orally, Week 1 - 16
Study NCT01405495 — intervention group
Intervention type: PROCEDURE
Intervention: MRI-based techniques (sMRI, fMRI, DTI, ASL)
Description: no drugs include
Study NCT01439646 — intervention group
Intervention type: OTHER
Intervention: it is a retrospective study, hence no active intervention
Description: since it is an observational restrospective study hence no active intervention is planned
Study NCT03450759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 Oral suspension (reference)
Description: Randomized subjects will receive single oral dose of AZD9977 oral suspension 15 mg/mL on Days 1, 3, 5 and 7 in Part A.
Study NCT03450759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 capsule
Description: Randomized subjects will receive single oral dose of AZD9977 capsule 65 mg on Days 1, 3, 5 and 7 in Part A.
Study NCT01399697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: orally, Week 17-28